Testing RZ-001 with valganciclovir for glioblastoma
Part of Cancer clinical trials.
This trial tests a new treatment called RZ-001 combined with an antiviral drug (valganciclovir) for people with glioblastoma, a serious brain tumor. The goal is to see if the combination is safe and can help shrink or slow the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with glioblastoma or a grade 4 astrocytoma (a type of brain tumor).
- Your tumor has a specific marker called hTERT (confirmed by a lab test).
- You are up and about and able to care for yourself most of the day (ECOG score 0–2).
- You have not had any other cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers expanded access to an experimental treatment (RZ-001) for people with recurrent glioblastoma (a type of brain cancer) that has grown again after initial treatment. It is for those who cannot join other clinical trials and aims to provide possible treatment options when standard ones have failed.
This trial tests a new injection called VRT106 for people whose glioblastoma (a brain tumor) has come back or is growing. It uses a virus that may help the immune system attack the tumor. This study is for those who have not had a similar virus or gene therapy before.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of two oral medications (vebreltinib and temozolomide) after surgery for a specific type of brain cancer called glioblastoma. The goal is to see if this combination can help stop the cancer from growing back.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This trial tests two new investigational drugs (ABBV-637, ABBV-155) combined with another drug (ERAS-801) for people with glioblastoma. The goal is to see if this combination can shrink the tumor or slow its growth. You need to have a specific genetic marker (EGFR amplification) in your tumor to be eligible.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.